Mulugeta Mulat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mulugeta Mulat has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Fazlurrahman Khan
Interdisciplinary Program of Marine and Fisheries Sciences and Convergent Technology, Pukyong National University, Busan 48513, Republic of Korea
3 shared publications Nazia Tabassum
Marine Integrated Biomedical Technology Center, The National Key Research Institutes in Universities, Pukyong National University, Busan, 48513, Republic of Korea
2 shared publications- Abirami Karthikeyan
Industry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan 48513, Republic of Korea
1 shared publication Aqib Javaid
Interdisciplinary Program of Marine and Fisheries Sciences and Convergent Technology, Pukyong National University, Busan 48513, Republic of Korea
1 shared publication- Aqib Javaid
Interdisciplinary Program of Marine and Fisheries Sciences and Convergent Technology, Pukyong National University, Busan 48513, Republic of Korea
1 shared publication - Geum-Jae Jeong
Department of Food Science and Technology, Pukyong National University, Busan 48513, Republic of Korea
1 shared publication
Latest Publications
- 10 March 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (3)
Multiple virulence attenuating strategies against Pseudomonas aeruginosa: Natural, synthetic, and synergistic approaches
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that causes severe acute and chronic infections, particularly in immunocompromised patients, those with cystic fibrosis, burn wounds, and structural lung disease. It has numerous virulence factors, including biofilm formation, quorum-sensing (QS) systems, exotoxins, and degradative enzymes, which make it pathogenic. All these factors combine to enhance tenaciousness, tissue destruction, and antimicrobial resistance. These virulence factors are being explored to inhibit multidrug-resistant microbes that are not susceptible to conventional antibiotics. Recent research has shown that synthetic molecules (such as enzyme antagonists, QS inhibitors, and novel chemical scaffolds), natural compounds (such as phytochemicals derived from plants, essential oils, and microbial metabolites), and synergistic combinations represent promising anti-virulence strategies. The use of nanomaterial-based synergistic delivery systems is vital for enhancing efficacy and targeted delivery. This review paper discusses the intriguing therapeutic properties of natural and synthetic agents, as well as their synergistic inhibitory effects, against various virulence factors that influence the strategies of multidrug-resistant bacteria, such as P. aeruginosa. Overall, these inhibitors enhance bactericidal activity by targeting multiple microbial pathways, with an emphasis on biofilm and QS systems, thereby addressing the problems of resilience and resistance development associated with conventional antibiotics. There are still issues with maximizing biocompatibility, pharmacokinetics, and clinical translation despite encouraging in vitro and preclinical results. This multifaceted strategy offers a lasting remedy for antibiotic-resistant P. aeruginosa infections, representing a paradigm shift from conventional bactericidal approaches to virulence attenuation. However, the possible adaptations of the pathogen and compensatory mutations to anti-virulence strategies need careful consideration.
- 10 March 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (3)
Multiple virulence attenuating strategies against Pseudomonas aeruginosa: Natural, synthetic, and synergistic approaches
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that causes severe acute and chronic infections, particularly in immunocompromised patients, those with cystic fibrosis, burn wounds, and structural lung disease. It has numerous virulence factors, including biofilm formation, quorum-sensing (QS) systems, exotoxins, and degradative enzymes, which make it pathogenic. All these factors combine to enhance tenaciousness, tissue destruction, and antimicrobial resistance. These virulence factors are being explored to inhibit multidrug-resistant microbes that are not susceptible to conventional antibiotics. Recent research has shown that synthetic molecules (such as enzyme antagonists, QS inhibitors, and novel chemical scaffolds), natural compounds (such as phytochemicals derived from plants, essential oils, and microbial metabolites), and synergistic combinations represent promising anti-virulence strategies. The use of nanomaterial-based synergistic delivery systems is vital for enhancing efficacy and targeted delivery. This review paper discusses the intriguing therapeutic properties of natural and synthetic agents, as well as their synergistic inhibitory effects, against various virulence factors that influence the strategies of multidrug-resistant bacteria, such as P. aeruginosa. Overall, these inhibitors enhance bactericidal activity by targeting multiple microbial pathways, with an emphasis on biofilm and QS systems, thereby addressing the problems of resilience and resistance development associated with conventional antibiotics. There are still issues with maximizing biocompatibility, pharmacokinetics, and clinical translation despite encouraging in vitro and preclinical results. This multifaceted strategy offers a lasting remedy for antibiotic-resistant P. aeruginosa infections, representing a paradigm shift from conventional bactericidal approaches to virulence attenuation. However, the possible adaptations of the pathogen and compensatory mutations to anti-virulence strategies need careful consideration.
- 21 August 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107232
Application of artificial intelligence in microbial drug discovery: Unlocking new frontiers in biotechnology
- 21 August 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107232
Application of artificial intelligence in microbial drug discovery: Unlocking new frontiers in biotechnology
- Top Cited PapersOpen Access
- 29 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (6) , 555
Multiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties
Biofilms are complex microbial communities encased within a self-produced extracellular matrix, which plays a critical role in chronic infections and antimicrobial resistance. These enhance pathogen survival and virulence by protecting against host immune defenses and conventional antimicrobial treatments, posing substantial challenges in clinical contexts such as device-associated infections and chronic wounds. Secondary metabolites derived from medicinal plants, such as alkaloids, tannins, flavonoids, phenolic acids, and essential oils, have gained attention as promising agents against biofilm formation, microbial virulence, and antibiotic resistance. These natural compounds not only limit microbial growth and biofilm development but also disrupt communication between bacteria, known as quorum sensing, which reduces their ability to cause disease. Through progress in nanotechnology, various nanocarriers such as lipid-based systems, polymeric nanoparticles, and metal nanoparticles have been developed to improve the solubility, stability, and cellular uptake of phytochemicals. In addition, the synergistic use of plant-based metabolites with conventional antibiotics or antifungal drugs has shown promise in tackling drug-resistant microorganisms and revitalizing existing drugs. This review comprehensively discusses the efficacy of pure secondary metabolites from medicinal plants, both as individuals and in nanoformulated forms or in combination with antimicrobial agents, as alternative strategies to control biofilm-forming pathogens. The molecular mechanisms underlying their antibiofilm and antivirulence activities are discussed in detail. Lastly, the current pitfalls, limitations, and emerging directions in translating these natural compounds into clinical applications are critically evaluated.
- 29 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (6) , 555
Top Cited PapersOpen AccessMultiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties
Biofilms are complex microbial communities encased within a self-produced extracellular matrix, which plays a critical role in chronic infections and antimicrobial resistance. These enhance pathogen survival and virulence by protecting against host immune defenses and conventional antimicrobial treatments, posing substantial challenges in clinical contexts such as device-associated infections and chronic wounds. Secondary metabolites derived from medicinal plants, such as alkaloids, tannins, flavonoids, phenolic acids, and essential oils, have gained attention as promising agents against biofilm formation, microbial virulence, and antibiotic resistance. These natural compounds not only limit microbial growth and biofilm development but also disrupt communication between bacteria, known as quorum sensing, which reduces their ability to cause disease. Through progress in nanotechnology, various nanocarriers such as lipid-based systems, polymeric nanoparticles, and metal nanoparticles have been developed to improve the solubility, stability, and cellular uptake of phytochemicals. In addition, the synergistic use of plant-based metabolites with conventional antibiotics or antifungal drugs has shown promise in tackling drug-resistant microorganisms and revitalizing existing drugs. This review comprehensively discusses the efficacy of pure secondary metabolites from medicinal plants, both as individuals and in nanoformulated forms or in combination with antimicrobial agents, as alternative strategies to control biofilm-forming pathogens. The molecular mechanisms underlying their antibiofilm and antivirulence activities are discussed in detail. Lastly, the current pitfalls, limitations, and emerging directions in translating these natural compounds into clinical applications are critically evaluated.